Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMFNH7L)

Drug Name
Pentobarbital Drug Info
Synonyms
Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
Therapeutic ClassHypnotics and Sedatives
Cross-matching ID
PubChem CID
4737
ChEBI ID
CHEMBL448
CAS Number
CAS 76-74-4
TTD Drug ID
D0F0YZ
INTEDE Drug ID
DR1254
ACDINA Drug ID
D01333

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 1.85 6.20e-2 101/150 (67.33%) HSPA8;HSPA6;HSPA1A;...
mRNA surveillance pathway 1.72 1.76e-1 71/98 (72.45%) NXF1;PPP1CB;DAZAP1;...
Th1 and Th2 cell differentiation 1.67 2.07e-1 80/92 (86.96%) NFKBIE;PRKCQ;JAG1;...
Proteasome 1.66 1.73e-1 44/46 (95.65%) PSMD2;PSMB3;PSMC4;...
Staphylococcus aureus infection 1.66 1.40e-1 72/95 (75.79%) KRT14;KRT16;KRT15;...
Type I diabetes mellitus 1.66 1.22e-1 38/43 (88.37%) HLA-DQA1;IL1B;PTPRN2;...
Estrogen signaling pathway 1.65 1.17e-1 119/137 (86.86%) HSPA8;GNAS;PLCB1;...
Dilated cardiomyopathy 1.60 1.86e-1 86/96 (89.58%) GNAS;AGT;ITGA4;...
Vascular smooth muscle contraction 1.59 1.85e-1 113/133 (84.96%) GNAS;PLCB1;AGT;...
Notch signaling pathway 1.56 2.09e-1 49/59 (83.05%) JAG1;NOTCH1;NCOR2;...
Graft-versus-host disease 1.54 2.20e-1 32/42 (76.19%) HLA-DQA1;IL1B;TNF;...
Leishmaniasis 1.46 4.00e-1 67/77 (87.01%) ITGA4;HLA-DQA1;IL1B;...
RNA polymerase 1.43 4.66e-1 23/31 (74.19%) POLR2E;POLR2L;POLR1D;...
Platelet activation 1.43 4.35e-1 106/124 (85.48%) GNAS;PLCB1;LYN;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.41 4.61e-1 79/89 (88.76%) NFKBIE;PRKCQ;CD3D;...
RNA transport 1.39 4.65e-1 128/186 (68.82%) NXF1;POP5;SEC13;...
Tuberculosis 1.39 4.62e-1 159/180 (88.33%) CD14;HLA-DQA1;FCER1G;...
Herpes simplex virus 1 infection 1.38 4.48e-1 165/498 (33.13%) NXF1;HLA-DQA1;IL1B;...
Long-term depression 1.38 4.55e-1 55/60 (91.67%) GNAS;PLCB1;LYN;...
Chagas disease 1.37 4.48e-1 93/102 (91.18%) GNAS;PLCB1;GNA15;...
Th17 cell differentiation 1.36 4.62e-1 95/107 (88.79%) NFKBIE;PRKCQ;HLA-DQA1;...
Amoebiasis 1.33 4.55e-1 99/102 (97.06%) CD14;GNAS;PLCB1;...
Inflammatory mediator regulation of TRP channels 1.32 4.62e-1 82/98 (83.67%) GNAS;PLCB1;PRKCQ;...
Relaxin signaling pathway 1.32 4.63e-1 114/129 (88.37%) MMP1;GNAS;PLCB1;...
Inositol phosphate metabolism 1.32 4.51e-1 66/73 (90.41%) PLCB1;IMPA2;PLCE1;...
Amphetamine addiction 1.32 4.41e-1 57/69 (82.61%) GNAS;MAOB;PPP1CB;...
T cell receptor signaling pathway 1.31 4.38e-1 93/104 (89.42%) NFKBIE;PRKCQ;CD3D;...
Carbohydrate digestion and absorption 1.31 4.34e-1 37/47 (78.72%) PLCB1;ATP1A2;SI;...
Toxoplasmosis 1.30 4.50e-1 103/112 (91.96%) HSPA8;HSPA6;HSPA1A;...
Parathyroid hormone synthesis, secretion and action 1.29 4.41e-1 98/106 (92.45%) GNAS;PLCB1;ADCY1;...
Prolactin signaling pathway -1.35 2.80e-1 66/70 (94.29%) STAT1;KRAS;CCND1;...
Amino sugar and nucleotide sugar metabolism -1.38 2.50e-1 38/48 (79.17%) PGM1;FPGT;RENBP;...
Arachidonic acid metabolism -1.41 2.16e-1 48/61 (78.69%) LTA4H;PLA2G3;CYP2U1;...
Lysosome -1.41 2.20e-1 115/128 (89.84%) SMPD1;LIPA;SCARB2;...
Glycosaminoglycan degradation -1.43 1.97e-1 19/19 (100%) GUSB;NAGLU;HEXA;...
Pantothenate and CoA biosynthesis -1.43 2.05e-1 14/21 (66.67%) COASY;BCAT1;BCAT2;...
NOD-like receptor signaling pathway -1.45 1.99e-1 145/181 (80.11%) BCL2L1;CASP1;BRCC3;...
TNF signaling pathway -1.45 2.07e-1 103/112 (91.96%) CASP8;BIRC2;CFLAR;...
Primary bile acid biosynthesis -1.46 1.97e-1 15/17 (88.24%) CH25H;SCP2;ACOT8;...
Pancreatic cancer -1.46 2.06e-1 75/76 (98.68%) RB1;RALB;BCL2L1;...
Glyoxylate and dicarboxylate metabolism -1.46 2.11e-1 23/30 (76.67%) HYI;CAT;DLD;...
One carbon pool by folate -1.47 2.15e-1 15/20 (75%) FTCD;MTHFD1;ATIC;...
Glioma -1.47 2.22e-1 67/75 (89.33%) ARAF;PLCG2;CDK4;...
Fluid shear stress and atherosclerosis -1.47 2.30e-1 123/139 (88.49%) GSTM3;SQSTM1;CAV2;...
Glycolysis / Gluconeogenesis -1.48 2.29e-1 56/67 (83.58%) HK2;ADH1A;ALDH3A1;...
Synaptic vesicle cycle -1.51 1.99e-1 63/78 (80.77%) ATP6V1E1;SLC6A3;TCIRG1;...
Cytokine-cytokine receptor interaction -1.54 1.65e-1 246/295 (83.39%) IL9R;IL22RA1;BMP6;...
Nitrogen metabolism -1.59 1.17e-1 16/17 (94.12%) CA12;CA14;GLUL;...
Rheumatoid arthritis -1.61 1.14e-1 78/93 (83.87%) ATP6V0C;HLA-DOB;ATP6V1H;...
Epithelial cell signaling in Helicobacter pylori infect... -1.68 6.12e-2 62/70 (88.57%) ATP6V1E1;MET;TCIRG1;...
Terpenoid backbone biosynthesis -1.68 6.15e-2 18/22 (81.82%) FNTB;HMGCR;GGPS1;...
Kaposi sarcoma-associated herpesvirus infection -1.69 6.84e-2 172/193 (89.12%) STAT1;IL6ST;CDK4;...
Collecting duct acid secretion -1.71 6.25e-2 22/27 (81.48%) SLC4A1;ATP6V1E1;TCIRG1;...
Phototransduction -1.72 6.04e-2 21/29 (72.41%) GUCY2D;RCVRN;PDE6G;...
Viral protein interaction with cytokine and cytokine re... -1.73 6.09e-2 84/100 (84%) IL6ST;CXCL9;CXCL12;...
Valine, leucine and isoleucine degradation -1.74 6.15e-2 42/48 (87.5%) BCAT2;ACAA2;AOX1;...
Synthesis and degradation of ketone bodies -1.77 6.01e-2 9/10 (90%) ACAT2;ACAT1;BDH1;...
Peroxisome -1.79 7.05e-2 72/82 (87.8%) DECR2;DAO;PEX6;...
Steroid biosynthesis -1.81 7.21e-2 19/20 (95%) TM7SF2;FDFT1;EBP;...
Butanoate metabolism -1.87 8.65e-2 23/28 (82.14%) ACAT2;ACAT1;BDH1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H